To be clear, this has next to nothing to do with Lilly’s “pen-form” dosings of a different formulation for diabetes / weight loss, one that will see list prices reduced NEXT YEAR (if ever) under a supposed Trump negotiated agreement.
No, this is a separate “make up on volume” what you drop in price VOLUNTARY marketing effort. And it will — I am sure — pay off handsomely for Lilly. [To be fair, if the pen form drops price in 2026 — it too will likely make it all back, on US volumes.]
Disclosure: I have long held a substantial Lilly position, since it was $560 or so, and it is now over… $1,030. But this entry point is also a fine one, as many analysts have the 12 month target above $1,200.
I admit that I’ve long believed sensible eating — along with vigorous exercise — are the best means to control weight. But given that diabetes (much of it related to obesity, in truth) has become a very high burden US disease, this fleet of drugs is absolutely going to sell into the mid-$30 billion of dollars per year, in the coming years. And that will (sort of sadly) persist, into the 2040s. So hop this train while you still might make a killing, on even modestly-invested dollars. [The risk of losing it all is only a smidge higher than a US government default on its own bonds.] Here’s the latest from CNBC.com:
…Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes.
Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients….
Eli Lilly’s stock… has climbed more than 36% this year…. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month….
Onward, now you know — Lilly once again played “rope-a-dope” on Tangerine. [Yes, this is my “power alley“.] And it all comes, as large lazy flakes are wheeling down now, almost in slow motion, on the updrafts — landing atop the foot of white stuff we already have down, here. Looks like the heavy metal shovel is in my future, once more, later this evening. Heh.
[Of course, as to all of the above, you should do your own due diligence. Out.]
नमस्ते